Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Oncol Rep ; 49(5)2023 May.
Article in English | MEDLINE | ID: mdl-36960864

ABSTRACT

The aim of the present study was to investigate the role of estrogen receptor (ER)α and ERß, and galectin­3 (GAL­3) in migration and invasion of androgen­independent DU­145 prostate cancer cells, and to examine the regulation of the expression of GAL­3 by the activation of these receptors. Wound healing and cell invasion assays were performed using the control (basal level of cellular function) and treated DU­145 cells. At 24 h of treatment, 17ß­estradiol (E2), the ERα­selective agonist, 4,4',4"­(4­propyl­(1H)­pyrazole­1,3,5­triyl)trisphenol (PPT), or the ERß­selective agonist, 2,3­bis(4­hydroxyphenyl)­propionitrile (diarylprepionitrile; DPN), increased the migration and invasion of the DU­145 cells. Pre­treatment with the ERα­ and ERß­selective antagonists blocked these effects, indicating that ERα and ERß are upstream receptors regulating these processes. Western blot analysis and immunofluorescence staining for the detection of the GAL­3 were performed using the control and treated DU­145 cells. Treatment of the DU­145 cells with E2, PPT or DPN for 24 h increased the expression of the GAL­3 compared to the control. Furthermore, a specific inhibitor of GAL­3 (VA03) inhibited the migration and invasion of DU­145 cells, indicating the involvement of the complex ERα/GAL­3 and ERß/GAL­3 in the regulation of these processes. On the whole, the present study demonstrates that the activation of both ERs increases the expression and signaling of GAL­3, and promotes the migration and invasion of DU­145 cells. The findings of the present study provide novel insight into the signatures and molecular mechanisms of ERα and ERß in DU­145 cells.


Subject(s)
Prostatic Neoplasms , Receptors, Estrogen , Male , Humans , Estrogen Receptor alpha/metabolism , Galectin 3 , Androgens , Estrogen Receptor beta/genetics , Estrogen Receptor beta/metabolism , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Estradiol/pharmacology
2.
J Ethnopharmacol ; 278: 114255, 2021 Oct 05.
Article in English | MEDLINE | ID: mdl-34062248

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Green propolis is produced by Apis mellifera honeybees using Baccharis dracunculifolia D.C. (Asteraceae) as substrate. This Southern Brazilian native plant and green propolis have been used in traditional medicine to treat gastric diseases, inflammation and liver disorders. AIM OF THE STUDY: Investigate the effects of baccharin (Bac) or p-coumaric acid (pCA) isolated from B. dracunculifolia D.C. (Asteraceae) over the inflammation induced by lipopolysaccharide (LPS) in vivo. MATERIALS AND METHODS: Inflammation was induced by LPS injection into air-pouches in mice, which were subsequently treated with Bac or pCA. Lavage fluid was collected from air pouches for the quantification of cellular influx via microscopy, and quantification of inflammatory mediators via colorimetric methods, ELISA and liquid chromatography-tandem mass spectrometry (LC-MS/MS). RESULTS: LPS-induced inflammation increased cellular influx and increased the levels of parameters related to vascular permeability and edema formation, such as nitric oxide (NO) and protein extravasation. Moreover, LPS increased the levels of cytokines and eicosanoids in the air-pouches. Importantly, both Bac and pCA suppressed the infiltration of neutrophils, production of NO and protein extravasation. Notably, the compounds promote differential regulation of cytokine and eicosanoid production. CONCLUSIONS: Our results suggest that Bac from green propolis directly affects inflammation by inhibiting the production of cytokines and eicosanoids, while pCA may exert direct, but also indirect effects on inflammation by stimulating the production of regulatory effectors such as interkeukin-10 in vivo.


Subject(s)
Baccharis/chemistry , Coumaric Acids/pharmacology , Propolis/metabolism , Trichothecenes/pharmacology , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Bees , Brazil , Coumaric Acids/isolation & purification , Cytokines/metabolism , Eicosanoids/metabolism , Female , Inflammation/drug therapy , Lipopolysaccharides , Male , Mice , Mice, Inbred BALB C , Plant Extracts/chemistry , Trichothecenes/isolation & purification
3.
Medicines (Basel) ; 8(5)2021 Apr 30.
Article in English | MEDLINE | ID: mdl-33946188

ABSTRACT

Background: Cutaneous melanoma is the most aggressive form of skin cancer, with the worst prognosis, and it affects a younger population than most cancers. The high metastatic index, in more advanced stages, and the high aggressiveness decrease the effectiveness of currently used therapies, such as surgical removal, radiotherapy, cryotherapy, and chemotherapy, used alone or in combination. Based on these disadvantages, research focused on alternative medicine offers great potential for therapeutic innovation. Medicinal plants represent a remarkable source of compounds for the treatment of various diseases. Methods: In this study, we investigated the tumoral behavior of melanoma under treatment with the compounds baccarin and p-coumaric acid, extracted from green propolis, in mice inoculated with B16F10 cells for 26 days. Results: A significant modulation in the number of inflammatory cells recruited to the tumor region and blood in the groups treated with the compounds was observed. In addition, a significant reduction in the amount of blood vessels and mitosis in the neoplastic area was noticed. Conclusions: Through our research, we confirmed that baccarin and coumaric acid, isolated substances from Brazilian green propolis, have a promising anticarcinogenic potential to be explored for the development of new antitumor agents, adhering to the trend of drugs with greater tolerance and biological effectiveness.

4.
Carbohydr Res ; 498: 108155, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33010570

ABSTRACT

The synthesis of MUC1 glycopeptides bearing modified tumor-associated carbohydrate antigens (TACAs) represents an effective strategy to develop potential antitumor vaccines that trigger strong immune response. In this context, we present herein the multistep synthesis of the triazole glycosyl amino acid Neu5Ac-α/ß2-triazole-6-ßGalNAc-ThrOH 1 as STn antigen analog, along with its assembly on the corresponding MUC1 peptide to give NAcProAsp [Neu5Acα/ß2-triazole-6-ßGalNAc]ThrArgProGlyOH 2. Despite interacting differently with SM3 monoclonal antibody, as shown by molecular dynamic simulations, this unnatural triazole glycopeptide may represent a promising candidate for cancer immunotherapy.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate/chemistry , Glycopeptides/chemistry , Glycopeptides/chemical synthesis , Mucin-1/chemistry , Triazoles/chemistry , Chemistry Techniques, Synthetic
5.
Tetrahedron ; 71(39): 7344-7353, 2015 Sep 30.
Article in English | MEDLINE | ID: mdl-26435551

ABSTRACT

Reaction of 2-(2-(2-azidoethoxy)ethoxy)ethyl 6-O-(prop-2-ynyl)-ß-d-galactopyranoside (7) under CuAAC conditions gives rise to mixed cyclic and linear triazole-linked oligomers, with individual compounds up to d.p. 5 isolable, along with mixed larger oligomers. The linear compounds resolve en bloc from the cyclic materials by RP HPLC, but are separable by gel permeation chromatography. The triazole-linked oligomers-pseudo-galactooligomers-were demonstrated to be acceptor substrates for the multi-copy cell surface trans-sialidase of the human parasite Trypanosoma cruzi. In addition, these multivalent TcTS ligands were able to block macrophage invasion by T. cruzi.

6.
Chembiochem ; 15(10): 1495-507, 2014 Jul 07.
Article in English | MEDLINE | ID: mdl-24920542

ABSTRACT

This study describes the synthesis of glycopeptides NHAc[ßGal]-(Thr)2 -[αGalNAc]-(Thr)2 -[αGlcNAc]-(Thr)2 Gly-OVA (1-OVA) and NHAc[ßGal-αGalNAc]-(Thr)3 -[αLacNAc]-(Thr)3 -Gly-OVA (2-OVA) as mimetics of both T. cruzi and tumor mucin glycoproteins. These glycopeptides were obtained by solid-phase synthesis, which involved the prior preparation of the protected glycosyl amino acids αGlcNAc-ThrOH (3), αGalNAc-ThrOH (4), ßGal-ThrOH (5), αLacNAc-ThrOH (6), and ßGal-αGalNAc-ThrOH (7) through glycosylation reactions. Immunizations of mice with glycopeptides 1-OVA and 2-OVA induced high antibody titers (1:16 000), as verified by ELISA tests, whereas flow cytometry assays showed the capacity of the obtained anti-glycopeptides 1-OVA and 2-OVA antibodies to recognize both T. cruzi and MCF-7 tumor cells. In addition, antisera induced by glycopeptides 1-OVA and 2-OVA were also able to inhibit T. cruzi fibroblast cell invasion (70 %) and to induce antibody-mediated cellular cytotoxicity (ADCC) against MCF-7 cells, with 50 % reduction of cell viability.


Subject(s)
Antibodies/immunology , Antibodies/pharmacology , Chagas Disease/therapy , Glycopeptides/immunology , Mucins/immunology , Neoplasms/therapy , Trypanosoma cruzi/drug effects , Amino Acid Sequence , Animals , Cell Line, Tumor , Cell Survival/drug effects , Chagas Disease/immunology , Chagas Disease/parasitology , Glycopeptides/administration & dosage , Glycopeptides/chemistry , Humans , Immunization , Mice , Mucins/administration & dosage , Mucins/chemistry , Neoplasms/chemistry , Neoplasms/immunology , Ovalbumin/administration & dosage , Ovalbumin/chemistry , Ovalbumin/immunology , Trypanosoma cruzi/chemistry , Trypanosoma cruzi/immunology , Trypanosoma cruzi/physiology
7.
Bioorg Med Chem ; 21(7): 1978-87, 2013 Apr 01.
Article in English | MEDLINE | ID: mdl-23415086

ABSTRACT

This work addresses the synthesis and biological evaluation of glycosyl diketopiperazines (DKPs) cyclo[Asp-(αGalNAc)Ser] 3 and cyclo[Asp-(αGalNAc)Thr] 4 for the development of novel anti-trypanosomal agents and Trypanosoma cruzi trans-sialidase (TcTS) inhibitors. The target compounds were synthetized by coupling reactions between glycosyl amino acids αGalNAc-Ser 7 or αGalNAc-Thr 8 and the amino acid (O-tBu)-Asp 17, followed by one-pot deprotection-cyclisation reaction in the presence of 20% piperidine in DMF. The protected glycosyl amino acid intermediates 7 and 8 were, in turn, obtained by α-selective, HgBr2-catalysed glycosylation reactions of Fmoc-Ser/Thr benzyl esters 12/14 with αGalN3Cl 11, being, subsequently, fully deprotected for comparative biological assays. The DKPs 3 and 4 showed relevant anti-trypanosomal effects (IC50 282-124 µM), whereas glycosyl amino acids 1 and 2 showed better TcTS inhibition (57-79%) than the corresponding DKPs (13-25%).


Subject(s)
Acetylgalactosamine/chemistry , Acetylgalactosamine/pharmacology , Diketopiperazines/chemistry , Diketopiperazines/pharmacology , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Acetylgalactosamine/chemical synthesis , Animals , Cell Line , Cells, Cultured , Chagas Disease/drug therapy , Chagas Disease/parasitology , Diketopiperazines/chemical synthesis , Glycoproteins/antagonists & inhibitors , Glycoproteins/metabolism , Glycosylation , Humans , Mice , Mice, Inbred C57BL , Mucins/chemistry , Mucins/pharmacology , Neuraminidase/antagonists & inhibitors , Neuraminidase/metabolism , Trypanocidal Agents/chemical synthesis , Trypanosoma cruzi/enzymology
8.
Bioorg Med Chem ; 20(1): 145-56, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-22154559

ABSTRACT

This work describes the synthesis of a series of sialylmimetic neoglycoconjugates represented by 1,4-disubstituted 1,2,3-triazole-sialic acid derivatives containing galactose modified at either C-1 or C-6 positions, glucose or gulose at C-3 position, and by the amino acid derivative 1,2,3-triazole fused threonine-3-O-galactose as potential TcTS inhibitors and anti-trypanosomal agents. This series was obtained by Cu(I)-catalysed azide-alkyne cycloaddition reaction ('click chemistry') between the azido-functionalized sugars 1-N(3)-Gal (commercial), 6-N(3)-Gal, 3-N(3)-Glc and 3-N(3)-Gul with the corresponding alkyne-based 2-propynyl-sialic acid, as well as by click chemistry reaction between the amino acid N(3)-ThrOBn with 3-O-propynyl-GalOMe. The 1,2,3-triazole linked sialic acid-6-O-galactose and the sialic acid-galactopyranoside showed high Trypanosoma cruzitrans-sialidase (TcTS) inhibitory activity at 1.0mM (approx. 90%), whilst only the former displayed relevant trypanocidal activity (IC(50) 260µM). These results highlight the 1,2,3-triazole linked sialic acid-6-O-galactose as a prototype for further design of new neoglycoconjugates against Chagas' disease.


Subject(s)
Antiparasitic Agents/chemical synthesis , Antiparasitic Agents/pharmacology , Drug Design , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Glycoconjugates/chemistry , Glycoproteins/antagonists & inhibitors , Neuraminidase/antagonists & inhibitors , Triazoles/chemistry , Trypanosoma cruzi/drug effects , Alkynes/chemistry , Antiparasitic Agents/chemistry , Azides/chemistry , Catalysis , Click Chemistry , Copper/chemistry , Enzyme Inhibitors/chemistry , Glycoconjugates/chemical synthesis , Glycoconjugates/pharmacology , Glycoproteins/metabolism , Neuraminidase/metabolism , Sialic Acids/chemistry , Trypanosoma cruzi/enzymology
9.
Bioorg Med Chem ; 18(7): 2412-27, 2010 Apr 01.
Article in English | MEDLINE | ID: mdl-20335038

ABSTRACT

Trypanosoma cruzi trans-sialidase (TcTS) plays a key role in the recognition and invasion of host cells and in enabling the parasite to escape the human immune response. To explore this potential drug target, we have synthesized a small library of substrate analogues based on 1,4-disubstituted 1,2,3-triazole derivatives of galactose modified at either the C-1 or C-6 positions. This was achieved by coupling the appropriate azido-sugars with a panel of 23 structurally diverse terminal alkynes by using the copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) reaction, giving a library of 46 derivatives in good to excellent yield and with complete regioselectivity. The sugar triazoles showed weak inhibition towards TcTS-catalyzed hydrolysis of 2'-(4-methylumbelliferyl)-alpha-d-N-acetylneuraminic acid in vitro (<40% inhibition at 1mM concentration); many of the compounds assessed proved to be acceptor substrates for the enzyme. Despite this modest inhibitory activity, in vitro trypanocidal activity assays against the trypomastigote form of T. cruzi Y strain revealed several compounds active in the low 100s of muM range. Further assessment of these compounds against cultured mouse spleen cells suggests a specific mode of anti-parasite action rather than a generic cytotoxic effect.


Subject(s)
Galactose/analogs & derivatives , Galactose/chemical synthesis , Neuraminidase/antagonists & inhibitors , Triazoles/chemical synthesis , Triazoles/pharmacology , Trypanocidal Agents/chemical synthesis , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology , Animals , Azides/chemical synthesis , Cell Line , Cell Survival/drug effects , Chromatography, Thin Layer , Fluorometry , Galactose/pharmacology , Indicators and Reagents , Magnetic Resonance Spectroscopy , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , N-Acetylneuraminic Acid/chemistry , N-Acetylneuraminic Acid/metabolism , Spectrometry, Mass, Electrospray Ionization , Spectrophotometry, Ultraviolet , Spleen/cytology , Spleen/drug effects , Structure-Activity Relationship
10.
Curr Drug Metab ; 10(2): 188-205, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19275553

ABSTRACT

About 50% of therapeutic drugs are currently administered as a racemate, a mixture of equal proportions of two enantiomers. In an achiral environment, the enantiomers of a chiral drug show identical chemical and physical properties. However, they can present different chemical and pharmacological behavior in a chiral environment such as in the body. The interaction of two enantiomers with a chiral macromolecule, such as an enzyme or receptor, is three dimensional in nature, forming diastereomeric complexes resulting in a chiral recognition process. Moreover, when administered as a racemate, two enantiomers can display the pharmacokinetic processes (absorption, distribution, metabolism and excretion) in a stereoselective manner. Among these processes, stereoselectivity plays a central role in the metabolism due to the involvement of the enzymatic system. Thus, the purpose of the current review is to present important aspects related to stereochemistry of drug metabolism, with emphasis on molecular mechanisms involved in enzyme mediated reactions, such as those catalyzed by cytochrome P450, uridine 5'-diphospho (UDP)-glucuronosyltransferases and sulfotransferases. Additionally, recent advances regarding the analysis of chiral drugs and their metabolites employing different analytical techniques (high-performance liquid chromatography-HPLC and capillary electrophoresis-CE) will also be outlined.


Subject(s)
Pharmaceutical Preparations/metabolism , Pharmacokinetics , Chromatography, High Pressure Liquid/methods , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Electrophoresis, Capillary/methods , Glucuronosyltransferase/metabolism , Humans , Stereoisomerism , Sulfotransferases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL